Medical research links shingles vaccines to lower dementia risk and identifies new neuralgia drivers

New medical research is shedding light on the mechanisms of postherpetic neuralgia and the broader neurological benefits of shingles vaccinations.

Studies published in the Annals of Neurology suggest that exosomes in the blood may play a critical role in postherpetic neuralgia. These particles appear to inhibit the growth of pain-sensing neurons and alter gene activity, potentially causing cells to become hypersensitive to pain signals even after the initial shingles rash has subsided. This discovery provides new targets for AI-supported therapies aimed at addressing the underlying causes of nerve irritation rather than just managing symptoms.

Separately, research from Brown University involving over 500,000 individuals indicates that the Shingrix shingles vaccine may reduce the risk of dementia by approximately 24 percent. Analyzing Medicare data from 2017 to 2022, researchers found that the dementia rate among vaccinated individuals was 18.8 percent after four years, compared to 24.6 percent in the unvaccinated group. While the effect was less pronounced in men and those previously vaccinated with Zostavax, the findings suggest that shingles immunization could offer significant cognitive protection.